| Page 48 | Cafepharma

You are here

Primary tabs

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

Post date: July 25, 2018 - 9:49am

Finch Therapeutics Expands Microbiome IP Portfolio with Six New Patents

Post date: July 25, 2018 - 8:59am

More Positive Results For Takeda's Alunbrig Acquisition

Post date: July 25, 2018 - 8:49am

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Post date: July 24, 2018 - 10:17am

Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine

Post date: July 24, 2018 - 9:55am

Gilead Announces Data on Truvada for HIV Prophylaxis

Post date: July 24, 2018 - 9:43am

Microbiome Report for the week ending 7-21-18

Post date: July 23, 2018 - 4:49pm

[sponsored] How to Use Speaker Book's Filters to Track Financial Disclosures

Post date: July 23, 2018 - 4:38pm

Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug

Post date: July 23, 2018 - 9:57am

Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis

Post date: July 23, 2018 - 9:40am

Pages